This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human CD27 / TNFRSF7 Protein, Fc Tag (HPLC verified)
catalog :
CD7-H5254
quantity :
200 ug, 1 mg
price :
270 USD, 1200 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
CD7-H5254
product name :
Human CD27 / TNFRSF7 Protein, Fc Tag (HPLC verified)
quantity :
200 ug, 1 mg
price :
270 USD, 1200 USD
quantity & price :
$270/200ug,$1200/1mg
target :
CD27
host species :
Human
By Tag :
Fc Tag
Research :
For Research Use Only
Source :
Human CD27, Fc Tag (CD7-H5254) is expressed from human 293 cells (HEK293). It contains AA Thr 21 - Ile 192 (Accession # NP_001233).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human CD27, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
CD Antigen CD27 is also known as Tumor necrosis factor receptor superfamily member 7 (TNFRSF7), which belongs to TNF-receptor superfamily. CD27 / TNFRSF7 is found in most T-lymphocytes. CD27 / TNFRSF7 is required for generation and long-term maintenance of T cell immunity. It binds to ligand CD70, and plays a key role in regulating B-cell activation and immunoglobulin synthesis. This receptor transduces signals that lead to the activation of NF-κB and MAPK8/JNK. CD27 has been shown to interact with SIVA1, TRAF2 and TRAF3.
References :
(1) Zhang Z., et al., 2004, Protein Sci. 13:2819-2824.
(2) Gravestein L.A., et al., 1998, Eur. J. Immunol. 28:2208-2216.
(3) Prasad K.V.S., et al., 1997, Proc. Natl. Acad. Sci. U.S.A. 94:6346-6351.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments